Kythera Acquires Rights to PGD2 Blocking Setipriprant for New Hair Loss Treatment
Collapse
X
-
-
setipiprant was shelved by the last company, and we didn't hear about any of their trial patients regrowing hair, even though that's not what they were testing it for. Still kinda intriguing, but even if it does help, how long will this take to get to market? Haven't even had a phase I yet. Also, can we get a hold of this stuff anywhere? Seems to have been safe for allergy sufferers to take in three trials, and should be easy enough to see if it works for hair. -
setipiprant was shelved by the last company, and we didn't hear about any of their trial patients regrowing hair, even though that's not what they were testing it for. Still kinda intriguing, but even if it does help, how long will this take to get to market? Haven't even had a phase I yet. Also, can we get a hold of this stuff anywhere? Seems to have been safe for allergy sufferers to take in three trials, and should be easy enough to see if it works for hair.Comment
-
"... Actelion will be eligible to receive up to $27 million in potential development and regulatory milestones, as well as royalties on sales if setipiprant is successfully commercialized.."
Wow, thats good money. Very interesting, thanks for postingComment
-
Chief Medical Officer of Kythera: "These observations are potentially the most innovative new thinking in hair loss over the last two decades (Think Propecia). Setipriprant is believed to directly affect this hair loss pathway, and our own preclinical and in vitro human hair models confirmed this effect. It is a well-characterized molecule with a large safety database and we believe we can quickly initiate a development program to study it in hair loss. Putting these two pieces of the puzzle together is ideal and represents an example of our approach to scientifically sound and efficient drug development."
If this isn't great news, I don't know what is.Comment
-
-
It all sounds good, the only thing that bothers me is that Actelion shelved the drug and never mentioned anything about hair. I know that Graza ad Cots have been trying to find the right PGD2 drug for a while though, maybe this is a good candidate.Comment
-
Its interesting that actelion will continue developing the stuff on their own.Comment
-
Cotsarellis' research found elevated pgd2 in bald scalps.
Pgd2 receptors can be blocked by a safe clinically trialled drug.
A company has just acquired a worldwide patent for this drug, after a period of curious silence from cotsarelis.
Somebody wanna get Kane on this, IMMEDIATELY!!Comment
-
Frederick Beddingfield, MD, PhD
Specialtyermatology
Department Affiliation:Medicine, Dermatology
Hospital Affiliation:Ronald Reagan UCLA Medical Center
Phone:310-825-6911
This guy is the head of research at Kythera. Someone should give him a call or set up a dermatology appointment with him (if you're in cali) and ask him why they think setipriprant has potential for hair loss, and how they plan to use it, topically or orally. Could be huge for forum people, if we can get this compound and figure out how to use it it might be a big help. Curiously, he also has worked for Allergan, the company developing bimatoprost. If I was in cali I'd definitely try to set up an appointment with him, he probably has a lot to say on hairloss.Comment
-
"All subjects completed the study. Both formulations were well tolerated, with headache the most frequently reported adverse event (25% of subjects), followed by flatulence (15%) and somnolence and fatigue (10%). The adverse event profile in men and women and between formulations was similar."
hmmmmmm headaches? not so fun. I'll fart all day for a full head of hair though. These are some pretty high side effect percentages, I hope they do make a topical version.Comment
Comment